指南与共识骨肌儿科影像

2021年美国风湿病学会幼年特发性关节炎治疗指南:非药物治疗、药物监测、免疫接种和影像学建议

2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging.
指南 / 共识 · Arthritis Rheumatol · 2022-03-01

该指南针对幼年特发性关节炎(JIA)的非药物治疗、药物监测、免疫接种和影像学检查提出建议,不限定JIA表型。采用PICO问题、系统文献综述和GRADE方法评级证据质量,投票小组(含临床医生和患者/照护者)达成推荐方向和强度共识。所有推荐证据质量均为低或极低,超过半数推荐为有条件推荐。

要点

  • 推荐使用物理治疗和职业治疗干预。
  • 推荐健康、均衡、适龄饮食。
  • 推荐广泛接种疫苗并与患者/照护者共同决策。

核心结论

  • 该指南为JIA患者的非药物治疗、药物监测、免疫接种和影像学管理提供推荐,证据质量低或极低,多数推荐为有条件推荐,临床决策应由治疗临床医生与患者/照护者共同做出。

研究设计与样本

  • 指南制定:美国风湿病学会;方法:提出PICO问题,系统文献综述,采用GRADE方法评级证据质量(高、中、低、极低),投票小组(包括临床医生和患者/照护者)达成推荐方向和强度(强或有条件)共识。

诊断标准与关键数值

  • 推荐使用物理治疗和职业治疗干预。
  • 推荐健康、均衡、适龄饮食。
  • 推荐特定药物实验室监测。
  • 推荐广泛使用免疫接种。
  • 推荐与患者/照护者共同决策。

临床应用与阅片要点

  • 该指南补充2019年美国风湿病学会JIA和葡萄膜炎指南及同期2021年关于少关节炎、颞下颌关节炎和全身型JIA的指南。
  • 推荐考虑关节和非关节表现的严重程度以及患者生活质量。
  • 临床决策应由治疗临床医生与患者/照护者共同做出。

局限性

  • 所有推荐证据质量均为低或极低。
  • 超过半数推荐为有条件推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To provide recommendations for the management of juvenile idiopathic arthritis (JIA) with a focus on nonpharmacologic therapies, medication monitoring, immunizations, and imaging, irrespective of JIA phenotype.

METHODS: We developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.

RESULTS: Recommendations in this guideline include the use of physical therapy and occupational therapy interventions; a healthy, well-balanced, age-appropriate diet; specific laboratory monitoring for medications; widespread use of immunizations; and shared decision-making with patients/caregivers. Disease management for all patients with JIA is addressed with respect to nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional.

CONCLUSION: This clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis, and a concurrent 2021 guideline on oligoarthritis, temporomandibular arthritis, and systemic JIA. It serves as a tool to support clinicians, patients, and caregivers in decision-making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision-making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient/caregiver.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Onel, Horton, Lovell, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis Rheumatol. 2022. PMID: 35233961. doi:10.1002/art.42036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。